Status:
COMPLETED
the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma
Lead Sponsor:
National Cancer Institute, Egypt
Conditions:
Pheochromocytoma
Eligibility:
All Genders
12-69 years
Phase:
PHASE2
Brief Summary
Pheochromocytoma (pheo) is a catecholamine secreting tumor arising from chromaffin cells of the adrenal medulla in 90% of cases \& in 10% is extra-adrenal arising from the sympathetic chain. It is mal...
Detailed Description
Pheochromocytoma (pheo) is a catecholamine secreting tumor arising from chromaffin cells of the adrenal medulla in 90% of cases \& in 10% is extra-adrenal arising from the sympathetic chain. It is mal...
Eligibility Criteria
Inclusion
- Age 12-69 years
- ASA physical status I \&II
- Surgically diagnosed pheochromocytoma, "unilateral or bilateral, adrenal or extra-adrenal". Diagnosis is confirmed radiologically with or without laboratory Vanillyl Mandelic Acid (VMA) level.
- Accepted Echo-heart data (EF ≥ 55%, no serious valve lesion) apart from hypertensive concentric ventricular hypertrophy \& diastolic dysfunction grade I \&II.
Exclusion
- Extremes of age
- ASA III \& IV
- History of cardiac (MI \& IHD) or cerebral (CVS) events
- History of major reaction to the used drugs
- History of major muscle, endocrinal or hematologic disorders
- Pregnant and lactating women
- Poor Echo-heart findings e.g. EF \< 55%, severe valve lesions \& severe pulmonary hypertension.
Key Trial Info
Start Date :
June 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04320589
Start Date
June 30 2019
End Date
August 30 2021
Last Update
September 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Anesthesia and Pain medicine.National Cancer Institute
Cairo, Egypt, 11796